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Abstract
Background: Cardiovascular disease is the leading cause of death worldwide with coronary artery disease
(CAD) making up a majority of those deaths. Coronary artery diseases are atherosclerotic or thrombotic in
nature leading to a disparity of blood in the coronary arteries and subsequent infarction of heart muscle.
Influenza has been established as a pro-inflammatory agent that has been implicated in increased death rates
from cardiovascular disease. With the establishment of this causal relationship, several trials were run to assess
the effect of the influenza vaccine on major cardiovascular risk factors, myocardial infarctions (MI), and
strokes. This review focuses on the effect of the influenza vaccine on major adverse cardiovascular events
(MACE) in patients with CAD.
Methods: An exhaustive search of available medical literature was performed using Medline-Ovid, Medline-
Pubmed, CINAHL and Web of science using the following keywords: influenza vaccine, heart diseases,
cardiovascular events, acute coronary syndrome, myocardial infarction, stroke, and angina pectoris. Relevant
studies were assessed for quality using GRADE.
Results: A 164 studies were reviewed for relevancy. Three studies met the inclusion criteria and were included
in this systematic review. All three of these randomized controlled trials (RCT) demonstrate a decrease in
major adverse cardiovascular events (MACE) in patients with CAD or acute coronary syndrome (ACS) with
the administration of the influenza vaccine: adjusted HR 0.67 (0.51-0.86), HR 0.54 (0.24-1.21), and RR 0.51
(0.30-0.86) respectively.
Conclusion: The influenza vaccine has shown a decrease in cardiovascular death, MI, unstable angina,
hospitalization, and ischemia in patients with already existing heart problems. This decrease in MACE has
been demonstrated for up to a year in all three studies with a two year follow up study showing a similar result.
The high quality of evidence presented from these studies, the low side effect profile of the influenza vaccine
as well as its low cost lead to a strong recommendation for the use of influenza vaccine in secondary
prevention of cardiovascular events in patients with CAD.
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Abstract   
 
Background: Cardiovascular disease is the leading cause of death worldwide with coronary 
artery disease (CAD) making up a majority of those deaths. Coronary artery diseases are 
atherosclerotic or thrombotic in nature leading to a disparity of blood in the coronary arteries and 
subsequent infarction of heart muscle. Influenza has been established as a pro-inflammatory 
agent that has been implicated in increased death rates from cardiovascular disease. With the 
establishment of this causal relationship, several trials were run to assess the effect of the 
influenza vaccine on major cardiovascular risk factors, myocardial infarctions (MI), and strokes. 
This review focuses on the effect of the influenza vaccine on major adverse cardiovascular 
events (MACE) in patients with CAD.  
 
Methods:  An exhaustive search of available medical literature was performed using Medline-
Ovid, Medline-Pubmed, CINAHL and Web of science using the following keywords: influenza 
vaccine, heart diseases, cardiovascular events, acute coronary syndrome, myocardial infarction, 
stroke, and angina pectoris. Relevant studies were assessed for quality using GRADE. 
 
Results:  A 164 studies were reviewed for relevancy. Three studies met the inclusion criteria and 
were included in this systematic review. All three of these randomized controlled trials (RCT) 
demonstrate a decrease in major adverse cardiovascular events (MACE) in patients with CAD or 
acute coronary syndrome (ACS) with the administration of the influenza vaccine: adjusted HR 
0.67 (0.51-0.86), HR 0.54 (0.24-1.21), and RR 0.51 (0.30-0.86) respectively.  
 
Conclusion:  The influenza vaccine has shown a decrease in cardiovascular death, MI, unstable 
angina, hospitalization, and ischemia in patients with already existing heart problems. This 
decrease in MACE has been demonstrated for up to a year in all three studies with a two year 
follow up study showing a similar result. The high quality of evidence presented from these 
studies, the low side effect profile of the influenza vaccine as well as its low cost lead to a strong 
recommendation for the use of influenza vaccine in secondary prevention of cardiovascular 
events in patients with CAD. 
 
Keywords: Influenza vaccine, heart diseases, cardiovascular events, acute coronary syndrome, 
myocardial infarction, stroke, angina pectoris  
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Occurrence of Cardiovascular Events in Patients with Coronary Artery Disease Receiving 
the Influenza Vaccine 
BACKGROUND 
Cardiovascular diseases are responsible for 17.3 million deaths globally with 42% of 
those deaths being attributed to coronary heart diseases.1 Atherosclerosis is most commonly 
implicated in coronary artery disease, progression of which can lead to thrombotic or embolic 
events such as myocardial infarctions (MIs) or strokes. Atherosclerosis itself is a chronic 
inflammatory disease of the arteries with pro-inflammatory properties.2,3 Inflammation of the 
intima of arteries leads to initial formation of plaque. Continued inflammation leads to the 
progression and rupture of said atherosclerotic lesions causing thrombosis of the involved 
arteries.3 
Studies have suggested that infections play a role in the atherosclerotic process as well. 
Acute infection in particular has been implicated in abrupt and severe inflammatory changes in 
atherosclerotic plaque which may lead to destabilization and rupture causing acute coronary 
syndrome (ACS) over a few days to weeks.3,4 Increasing incidences of MIs and strokes in the 
winter coinciding with upper respiratory tract infections (URIs)5 led to the study of the role of 
influenza infection in the development of atherosclerosis and the triggering of it’s complications. 
These studies revealed that influenza infection increases inflammation, smooth muscle cell 
proliferation and fibrin deposition in the arterial intima,6 confirming that influenza infection is 
both pro-inflammatory and prothrombotic.7 Another study affirms the increase in atherosclerosis 
with influenza infection and also denotes that more cardiovascular deaths are seen during 
influenza epidemics8 and risks of both MI and stroke are increased after an acute influenza 
infection.9 A subsequent study also shows that 19% of people suffering from an acute MI 
recalled having a URI in the past two weeks.5   
Conversely, studies of patients with acute infections treated with antibiotics10 suggests a 
strong involvement of the immune system in the development of atherosclerosis, namely due to 
the immunosuppression of B lymphocytes.11 Vaccinations are known to cause a rapid humoral 
response with activation and immediate migration of B lymphocytes to the site of the induced 
stimulus.11 The influenza vaccination in particular has been shown to create an immediate and 
significant immune response with viral antibodies found in the periphery for up to a week,12 
which presumably is what deters atherosclerosis. 
With the positive causal association between influenza infection and ACS,3,5,8,9 and the 
negative causal association between the influenza vaccination and atherosclerosis,10-12 the effect 
of influenza vaccination on ACS was studied. Several case control studies demonstrated that the 
influenza vaccine reduces risk of recurrent MI,13 primary cardiac arrest14 and all cause specific 
mortality.15 Several randomized controlled trials (RCTs) have also looked at the effect of 
influenza vaccine on patients with established heart disease but no guidelines or 
recommendations exist for or against the use of influenza vaccine in this population. This 
systemic review looks to see if cardiovascular events in patients with CAD can be decreased 
with the use of influenza vaccine and whether a recommendation for the use of this vaccine can 
be made.  
METHODS 
 An exhaustive search of available medical literature was performed using Medline-Ovid, 
Medline-Pubmed, CINAHL, and Web of science with the following keywords: influenza 
vaccine, heart diseases, cardiovascular events, acute coronary syndrome, myocardial infarction, 
stroke, and angina pectoris. The search was narrowed to use English language articles and human 
trials only. Studies to be considered for inclusion were required to use the influenza vaccine in 
patients with CAD or ACS, a subclass of CAD, and look at incidence of cardiovascular 
outcomes post vaccination. Bibliographies of relevant studies were looked at for further sources. 
Relevant articles were assessed for quality using Grading of Recommendations, Assessment, 
Development and Education (GRADE).24 
RESULTS 
A total of 164 studies were reviewed for relevancy. Four studies that focused primarily 
on the effects of influenza vaccine on patients with some form of CAD or ACS were considered 
for inclusion. One study13 was excluded on account of being a case control study leaving three 
RCTs17-19 for inclusion in this systematic review. Two follow up studies20-21 of the FLUVACS 
study19 were found and used as supplements. No additional studies were found by searching the 
references of the included studies. See Table I. 
Phrommintikul et al 
 This prospective randomized open with blinded endpoint (PROBE) study17 investigated 
the effect of influenza vaccination on cardiovascular events in patients with acute coronary 
syndrome. This study enrolled 439 patients all of whom had been admitted due to ACS sometime 
within the past 8 weeks and randomly allocated them to receive either the inactivated influenza 
vaccine in the vaccine group or no treatment in the control group. The primary endpoint being 
looked at was combined major adverse cardiovascular events (MACE) including: death, 
hospitalization from ACS, hospitalization from heart failure, and hospitalization from stroke. The 
secondary endpoint being studied was cardiovascular death. Both endpoints were verified by 
cardiologists who were unaware of patient group allocation.17 
 Eligibility criteria for patients were admission due to ACS within the past 8 weeks, age 
greater than 50 years, and agreement to participation. Patients were excluded if they had a serum 
creatinine level > 2.5mg/dL, significant liver disease, a hemoglobin level < 10g/dL, cancer, a life 
expectancy < 1 year, or contradictions to the influenza vaccine. The 439 eligible patients were 
randomly assigned to either the vaccine group or control group using a computer generated block 
randomization size of 4. A single dose intramuscular injection of 0.5ml of split, inactivated 
influenza vaccine was given to patients in the vaccine group. All patients were given the standard 
ACS treatment, including coronary revascularization, according to their primary cardiologists.17 
 Both treatment and control groups were balanced at all baseline characteristics. There 
were 221 patients randomized to the vaccine group and 218 patients randomized to the control 
group. About one third of the patients had STEMI (ST segment elevation MI), of which 75% 
received reperfusion therapy. Out of the patients with NSTEMI (non-ST segment elevation MI), 
33.3% underwent revascularization during admission and 15.7% underwent revascularization 
after admission, whereas 48.9% did not undergo any revascularization. Majority of the patients 
received standard medications including aspirin, beta blockers, and statins. Patients in the 
vaccine group received ACE inhibitors (ACE-I) more frequently than the control group. 
Intention to treat analysis was performed. Both groups had one loss to follow and no cross overs 
during the trial. The median time for follow up was 360 days for each group.17  
 Administration of the influenza vaccine resulted in decreased rates of MACE (9.5% vs 
19.3%, HR 0.70, CI 0.57-0.86, p = 0.004, NNT = 10) and hospitalization for ACS (4.5% vs 
10.6%, unadjusted HR 0.73, CI 0.55-0.91, p = 0.032). There wasn’t a significant difference in the 
rate of hospitalization for heart failure (1.8 vs 4.6%, unadjusted RR 0.9, CI 0.49-1.01, p = 0.111), 
total mortality (2.7 vs 5.5%, unadjusted HR 0.73, CI 0.50-1.03, p = 0.156) or incidence of 
cardiovascular death (2.3% vs 5.5%, unadjusted HR 0.39, CI 0.14-1.12, p = 0.088). The rates of 
MACE when adjusted for age, sex, serum creatinine, ACE-I, and coronary revascularization 
continued to be significantly lower for the vaccine group as compared to the control group 
(adjusted HR 0.67, CI 0.51-0.86, p = 0.005).17  
 The limitations of this study, as described by the authors are as follows: the open label 
design of the study may have compromised the validity of study by crossing over of patients 
from the control group to vaccination group, or by bias of the physicians towards more invasive 
treatment strategies for the control group. However, no crossing over occurred in this trial and 
the treatment strategies for ACS were planned before patient recruitment into this study. In 
addition, there was no active survey for influenza infection.17 
 Ultimately the authors recommend the use of the influenza vaccine as a secondary 
prevention in patients with ACS as it reduced the rates of MACE in these patients.17  
FLUCAD Study 
 In this randomized, double blind, placebo controlled study,18 the authors evaluated the 
effect of influenza vaccination on the coronary events in patients with confirmed CAD. This 
study enrolled 658 optimally treated CAD patients who were randomized to receive either the 
influenza vaccine or placebo vaccine. The randomization sequence was computer generated by 
an independent statistician. The syringes for vaccine and placebo were identical and labelled 
with randomization numbers according to a code and delivered to the trial site. The study nurses 
and all study personnel were blinded till the database was closed. The primary endpoint studied 
was 12 month cardiovascular death. The two secondary endpoints studied were MACE 
(composite of cardiovascular death, acute MI, or coronary revascularization) and coronary 
ischemic events (MACE or hospitalization for myocardial ischemia), both assessed at 12 month 
periods.18  
 The eligibility criteria for patients included age of 30-80 years and CAD confirmed by 
angiography with at least 50% stenosis of at least one large coronary artery. Patients with 
congestive heart failure, stage III or IV, planned cardiovascular surgery within 6 months, renal 
failure, neoplasm, psycho-organic disorders, factors impeding follow up, or any 
contraindications to vaccination were excluded. Patients in the vaccination group received a 
single intramuscular inactivated subunit influenza vaccine containing 0.5 ml dose hemagglutinin 
containing three strains of viral antigens or a placebo vaccine containing all of the components 
except for viral antigens. Patients hospitalized for percutaneous coronary interventions (PCIs) 
were vaccinated before the scheduled procedure while other patients were vaccinated at 
outpatient visits to cardiologists.18 
 The baseline characteristics of both vaccine and controls groups were similar. Of the 658 
total, 325 patients were randomized to the vaccine group and 333 patients were randomized to 
the placebo group. There were 157 patients who had primary PCI with ACS or unstable angina, 
131 patients had elective PCI with stable angina, and 370 outpatients had stable angina and 
confirmed CAD by angiography. Most of the patients received aspirin, statins, ACE-I and beta 
blockers. Median follow up for the patients was 298 days with no losses to follow up and no 
cross overs.18  
 The primary endpoint, cardiovascular death, occurred in two patients in each group. The 
estimated 12-month cumulative cardiovascular death rate was similar in both group as well 
(0.63% vs 0.76% in the placebo group, unadjusted HR 1.06, CI 0.15-7.56, p = 0.95). Two 
patients died of non-cardiovascular causes in each group as well leading to an overall mortality 
of three patients in each group. MACE occurred less frequently in the vaccine group (3.00% vs 
5.87%, HR 0.54, CI 0.24-1.21, p = 0.13, NNT 35) as did coronary ischemic events (6.02% vs 
9.97%, HR 0.54, CI 0.29-0.99, p = 0.047).18  
 The demographic, clinical, biochemical and angiographic data from this trial was also 
used to search for predictors of coronary ischemic events. Univariate analysis of seven factors, 
namely gender, influenza vaccination, history of heart failure, primary PCI for ACS, elective PCI 
for stable angina, and two nitrates was conducted revealing association with coronary ischemic 
events. Influenza vaccination was found to be a negative predictor associated with significant 
reduction of the risk of coronary ischemic events. Multivariate analysis also predicted that lack 
of influenza vaccination is as an independent predictors of coronary ischemic events (HR 0.38, 
CI 0.19-0.78, p = 0.0086).18 
 The authors of this study listed three limitations in their opinion. Firstly, there are a small 
number of cardiac events due to small sample size. The authors estimate that a sample size of 
2240 patients is needed to estimate optimal amounts of MACE events. Secondly the effect of the 
flu vaccination on restenosis is not known as routine angiography was not planned in this study. 
Lastly, there may have been a patient selection bias but PCI patients were recruited after 
successful angioplasty and congestive heart failure patients were excluded from this study thus 
there is a low risk of bias.18 
 In conclusion, the authors state that the influenza vaccination in addition to optimal 
medical treatment, improves the clinical course of CAD, reducing the frequency of MACE, 
coronary ischemic events and myocardial ischemia.18 
 
FLUVACS study 
 This study is a randomized, prospective, multicenter, single-blind, parallel group, 
controlled pilot study19 consisting of two different cohorts of patients: a clinical group including 
those patients with STEMI or NSTEMI occurring within the previous 72 hours and an 
intervention group of patients undergoing angioplasty/stenting. A total of 305 patients were 
enrolled, 204 in the clinical group and 101 in the intervention group, from six care units in 
Argentina. The primary outcome examined was cardiovascular death. The secondary outcome 
was the composite of cardiovascular death, nonfatal MI and severe recurrent ischemia in a six 
month follow up.19 
  The inclusion criteria consisted of patients over 21 years of age with an episode of angina 
at rest lasting at least 20 minutes and having occurred in the previous 72 hours. Definitive 
evidence of underlying heart ischemia was obtained using ECG changes and cardiac enzymes. 
Patient with evidence of hepatic or renal failure, congestive heart failure, terminal disease, 
contradictions to follow up, the vaccination or prior vaccination were excluded from the study. 
The clinical group was divided into two groups of a 100 patients each: group A received a single 
intramuscular vaccination of 0.5 mL of two different viral antigens while group B served as a 
control. The intervention group was divided into two groups as well: a group of 51 patients who 
received the influenza vaccination and 50 patients who served as control. A total of 151 patients 
were in the vaccination group and a 150 in the control. The two groups in both the intervention 
and clinical group were similar at baseline.19  
 The primary outcome of cardiovascular death occurred in 2% of the vaccine group as 
compared to 8% of the control group (RR 0.25, CI 0.07-0.86, p = 0.01, NNT 17). The triple 
composite end point consisting of cardiovascular death, nonfatal MI or severe ischemia occurred 
in 11% of vaccine group as compared to 23% in the control group (RR 0.51, CI 0.30-0.86, p = 
0.009, NNT 8). No patients were lost to follow up and intention to treat analysis was performed. 
The only limitation of this study per the authors was the inability to confirm further influenza 
infection in the population studied particularly in the control group as serological analysis was no 
performed.19 
 The conclusion of this pilot study of 301 patients was that vaccination was associated 
with a significant reduction of subsequent ischemia events in the clinical group.19 
DISCUSSION 
 Atherosclerosis is a chronic inflammatory condition of arterial intima2,3 which under the 
stress of an acute infection destabilizes and ruptures leading to ACS.3,4 Acute influenza infection 
is known to accelerate atherosclerosis and precipitate the occurrence of ACS.5,7,8 And the 
influenza vaccination has been shown to decrease recurrent MI, primary cardiac arrest, and all-
cause mortality.4,14,15 There are however no clear guidelines nor systematic review for the use of 
influenza vaccine to decrease cardiovascular events in patients with existing heart disease.  
 This systemic review used three studies17-19 that look specifically at the use of influenza 
vaccine to decrease cardiovascular events, namely MACEs, in patients with CAD or ACS. 
Phrommintikul et al17 showed a significant decrease in MACE in ACS patients receiving the 
Influenza vaccine (HR 0.70, CI 0.57-0.86, p = 0.004, NNT = 10). This decrease remained with 
the adjustment for variables as well as subgroup analysis (adjusted HR 0.67, CI 0.51-0.86, p = 
0.005). The FLUCAD study,18 the only placebo controlled RCT, found that influenza vaccination 
led to a decrease in MACE (HR 0.54, CI 0.24-1.21, p = 0.13), namely coronary ischemia events 
(HR 0.54, CI 0.29-0.99, p = 0.047), as well as a better MACE free survival in vaccinated patients 
versus control. In the FLUVACS study,19 vaccination showed a significant reduction in 
subsequent ischemic events (RR 0.25, CI 0.07-0.86, p = 0.01) and the triple composite endpoint 
(RR 0.51, CI 0.30-0.86, p = 0.009) in the clinical cohort within six months. The two follow up 
studies of the FLUVACS pilot study found a similar decrease in triple composite endpoint at one 
year20 (HR 0.59, CI 0.4-0.86, p = 0.004) and at two years21 (HR 0.36, CI 0.12-1.09, p = 0.05) as 
well. In addition to decreasing MACE, influenza vaccination was also proven to be a negative 
predictor of risk of coronary ischemic events by both univariate and multivariate analysis in the 
FLUCAD study (HR 0.38, CL 0.19-0.78, p = 0.0086).19 This results in an overall high quality of 
evidence and a strong recommendation is made in vaccinating against influenza in patients with 
CAD.  
 As far as cardiovascular death is concerned, the three studies do not share a complete 
consensus. Only the FLUVACS study19 documents a decrease in cardiovascular mortality with 
the use of vaccination in CAD patients at 6 months, 1 year and 2 years.19-21 The study by 
Phrommintikul et al17 and the FLUCAD study18 find no significant difference in cardiovascular 
death or all-cause mortality between the control and vaccination groups; however, the results 
were trending towards significance and may have achieved significance given enough time. 
Though the reason for this discrepancy in the results between studies is not known, it can be 
assumed that the low event rate may have played a role.  
 While all three studies have demonstrated the influenza vaccine to be affective in 
decreasing MACE, they do have some limitations (See table I). Two of the studies, 
Phrommintikul et al17 and the FLUVACs study18 are not placebo controlled. Though there no 
cross overs in either study, there was still a possibility of bias. Patients in the control group knew 
they were control by virtue of not getting a vaccine or placebo. 
 Another limitation of these studies is the small sample sizes. Though the FLUVACs 
study19 has the smallest population size, it is the FLUCAD study18 that states they may be 
underpowered to detect a statistical difference in mortality and MACE rates. The optimal sample 
size calculated by this study was 2240, a feat none of the three studies have accomplished.  
 Despite these limitations, influenza vaccination remains safe for use in CAD patients22 as 
it maintains very low side effect profile.17-19 Not only does the influenza vaccination benefit 
patients by decreasing their chances of getting influenza, it also decreases the prothrombotic 
events related to influenza. 7 In addition the influenza vaccine remains a cheap and easily 
available intervention for secondary prevention in CAD patients. Further studies are still needed 
to fully assess the effect of the influenza vaccine. Firstly, a larger scale or longer duration double 
blinded, placebo controlled trial is needed to obtain statistical significance in mortality and 
MACE rates. Secondly, a study on restenosis after administration of influenza vaccination is 
needed to fully determine the anti-inflammatory properties of the influenza vaccine. Lastly, a 
study on the cardiovascular effects of contracting influenza post influenza vaccination is needed 
to further understand the inflammatory properties of acute infections and the anti-inflammatory 
properties of the influenza vaccination.  
CONCLUSION 
 The influenza vaccine has been demonstrated to be a safe and cost effective method of 
decreasing major adverse cardiovascular events in patients with coronary artery disease and 
acute coronary syndrome. Specifically, the influenza vaccine has shown a decrease in the 
occurrence of ischemia, angina, and myocardial infarction in patients who are being optimally 
treated for their underlying heart disease. No benefits have been seen in terms of cardiovascular 
death or all-cause mortality although a benefit may be demonstrated with larger studies. The 
overall combined quality of the articles reviewed was high in the GRADE criteria. Based on 
these results, a strong recommendation can be made for the use of influenza vaccinations as a 
secondary prevention in patients with coronary artery disease.  Further research with larger 
population sizes and post vaccination angiography is needed to fully understand the impact of 
influenza vaccination in these patients as well to understand the mechanism by which influenza 
vaccine decreases atherosclerosis. The role of the humoral immunity and B lymphocytes needs 
further study as well.  
  
REFERENCES 
1. WHO. Cardiovascular Diseases. Geneva. 
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 
2005;352:1685-1695. 
3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126. 
4. Keller TT, van der Sluijs KF, de Kruif MD, GERDES VE, Meijers JC, Florquin S, van 
der Poll T, van Gorp EC, Brandjes DP, BUller HR, Levi M. Effects on coagulation and 
fibrinolysis induced by influenza in mice with a reduced capacity to generate activated 
protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 
2006;99:1261-1269. 
5. Meyers DG. Myocardial infarction, stroke, and sudden cardiac death may be prevented 
by influenza vaccination. Curr Atheroscler Rep. 2003;5:146-149. 
6. Naghavi M, Wyde P, Litovsky S, et al. Influenza infection exerts prominent 
inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-
deficient mice. Circulation. 2003;107:762-768. 
7. Madjid M, Aboshady I, Awan I, Litovsky S, Casscells SW. Influenza and cardiovascular 
disease: is there a causal relationship? Tex Heart Inst J. 2004;31:4-13. 
8. Gurevich VS, Pleskov VM, Levaya MV. Autoimmune nature of influenza atherogenicity. 
Ann N Y Acad Sci. 2005;1050:410-416. 
9. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of 
myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 
2004;351:2611-2618. 
10. Gurfinkel E, Bozovich G, Droca A, Beck E, Maumer B. Randomised trial of 
roxithromycin in non-Q-wave coronary syndomres: ROXIS pilot study. ROXIS Study 
Group. Lancet 1997;350:404-407. 
11. Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early 
humoral response in peripheral blood following parenteral inactivated influenza 
vaccination. Vaccine 1994;12:993-999. 
12. Brokstad KA, Cox RJ, Olofsson J, Jonsson R,Haaheim LR. Parenteral Influenza 
vaccination induces a rapid systemic and local immune response. J Infect Dis 1995; 
171:198-203. 
13. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of 
influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 
2000;102:3039-3045. 
14. Siscovick DS, Raghunathan TE, Lin D, weinmann S, Arbogast P, Lemaitre RN, Psaty 
BM, Alexander R, Cobb LA. Influenza vaccination and the risk of primary cardiac arrest. 
Am J Epidemiol 2000;152:674-677. 
15. Wang CS, Want ST, Lai CT, Lin LJ, Chou P. Impact of influenza vaccination on major 
cause-specific mortality. Vaccine 2007;25:1196-1203. 
16. GRADE working group. GRADE website. http://gradeworkinggroup.org/. Accessed 
November 10, 2014. 
17. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, 
Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with 
acute coronary syndrome. Eur Heart J. 2011;32:1730-1735. 
18. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary 
prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. 
Eur Heart J. 2008;29:1350-1358. 
19. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in 
acute coronary syndromes and planned percutaneous coronary interventions: the FLU 
Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 
2002;105:2143-2147. 
20. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute 
coronary syndromes and planned percutaneous coronary interventions (FLUVACS) 
Study. Eur Heart J. 2004;25:25-31. 
21. Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU Vaccination Acute 
Coronary Syndromes (FLUVACS) Registry. Tex Heart Inst J. 2004;31:28-32. 
22. Keshtkar-Jahromi M, Vakili H, Rahnavardi M, et al. Antibody response to influenza 
immunization in coronary artery disease patients: a controlled trial. Vaccine. 
2009;28:110-113. 
23. Leon de la Fuente R, Gurfinkel EP, Toledo D, Mautner B, Grupo de Estudio FLUVACS. 
Flu vaccination in patients with acute coronary syndromes: treatment benefit in 
prespecified subgroups. Rev Esp Cardiol. 2003;56:949-954. 
24. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elder 
persons: a meta-analysis and review of the literature. Ann Intern Med. 1995; 123:518-
527. 
  
Table I: GRADE Quality of Assessment and Summary of Findings  
 
a
 No placebo for control group hence only single blinded 
b
 Sample number of cardiac events due to small sample size; optimal estimated sample size should be 2240, study 
sample size was 658 
c RR < 0.5, RR = 0.25 
 
Quality Assessment   































MACE (cardiovascular death, MI, coronary revascularization) 
 
 















MACE (cardiovascular death, non-fatal MI, severe recurrent ischemia) 
 
 
FLUVACS19 RCT  
Serious 
limitationa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely 
Large 
magnitudec  
High  
